Agenus Inc

AGEN

$0.78

-70.1% last 12 months

Steven Cohen Holding value: $13.8 Million Jim Simons Holding value: $485 Thousand Paul Tudor Jones II Holding value: $294 Thousand Ken Griffin Holding value: $35.7 Thousand Robert Bruce Holding value: $0 Chuck Royce Holding value: $0 First Eagle Investments Holding value: $0 Ken Fisher Holding value: $0 Joel Greenblatt Holding value: $0 George Soros Holding value: $0

Market Cap

$296 Million

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$0.61 - $2.95

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

-1.09x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $296 Million
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $203 Million
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $0.00 (0.0%)
1 Year Return Profit or loss of share price change plus dividend yield. -70.1%
52-Week High Highest share price in the last 52 weeks. $2.95
52-Week Low Lowest share price in the last 52 weeks. $0.61
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 0.0
Outstanding Shares The number of shares the company has issued and are held by stockholders. 381 Million
Avg 30 Day Volume The number of shares traded in the last 30 days. 9.88 Million

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. -1.09
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. -7.45
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. -$0.79
Price to Sales Ratio Market cap divided by the revenue in the most recent year. Infinity
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company -0.78
Enterprise Value to Revenue Enterprise value divided by revenue 2.01
Enterprise Value to EBIT Enterprise Value divided by EBIT -0.95
Total Debt to Enterprise Value Total debt divided by enterprise value 0.06
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. -0.1

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $101 Million
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $90.4 Million
EBIT Earnings before tax and interest payments. -$213 Million
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. -$271 Million
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. -268.37%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. +14.7%
Return on Equity Equity divided by market cap. 209.72%
Return on Assets Indicates a company's profitability in relation to its total assets. -80.71%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. -155.61%

Insider trades

No purchases

No sells

No purchases

No sells

No purchases

No sells

No purchases

No sells

Q1 2023 Q2 2023 Q3 2023 Q4 2023

About Agenus Inc

CEO: Garo Armen

Industry: Biological Product (except Diagnostic) Manufacturing

Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators , patient-specific anti-cancer vaccines, and adjuvants that can be used with a range of vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients. In light of the advances made, Science magazine hailed cancer immunotherapy as its 2013 Breakthrough of the Year. Agenus was founded in 1994 by Garo H. Armen and Pramod K. Srivastava. The company has pioneered immunotherapies, including heat shock protein-based cancer vaccines, a program that has developed into its Prophage Series of personalized anti-cancer vaccines. Antigenics became a public company in February 2000 on the NASDAQ exchange with the ticker symbol AGEN. In 2000 Agenus acquired Aquila Biopharmaceuticals and a year later it acquired Aronex Pharmaceuticals. In February 2014 the company acquired a European firm, 4-Antibody, along with their portfolio of checkpoint modulators and a platform to rapidly and efficiently discover new antibodies.

Similar stocks

Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc.
Northwest Biotherapeutics Inc
Northwest Biotherapeutics Inc
Merck & Co Inc
Merck & Co Inc
GSK Plc - ADR
GSK Plc - ADR
Johnson & Johnson
Johnson & Johnson
Celldex Therapeutics Inc.
Celldex Therapeutics Inc.

News

Beguiling stocks: Agenus Inc (NASDAQ:AGEN), Philip Morris International Inc (NYSE:PM)

Beguiling stocks: Agenus Inc (NASDAQ:AGEN), Philip Morris International Inc (NYSE:PM)

AGEN has seen its SMA50 which is now -27.42%. In looking the SMA 200 we see that the stock has seen a -50.80%. PM has seen its SMA50 which is … The post Begu...

Stock Equity Stock Equity, 22 days ago
Agenus Inc (AGEN) Reports Q‘ —…—‘ Results: Revenue of $—4. ...

Agenus Inc (AGEN) Reports Q‘ —…—‘ Results: Revenue of $—4. ...

Agenus Inc (AGEN) Reports Q3 2023 Results: Revenue of $24.3 Million and Net Loss of $64.5 Million

GuruFocus GuruFocus, about 1 month ago
Agenus Inc.: Agenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma

Agenus Inc.: Agenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma

U.S. BLA Filing in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (CRC) Planned for Midyear 2024 Potential Accelerated Filings for Advanced Pancrea...

Finanz Nachrichten Finanz Nachrichten, about 2 months ago
ESMO 2023: Agenus’ Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes

ESMO 2023: Agenus’ Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes

Agenus Inc. (Nasdaq:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced expanded data from the company’s phase...

Wallstreet:Online Wallstreet:Online, about 2 months ago
Never miss a trade
To improve your user experience we use cookies.